Stimulatory peroxisome proliferator-activated receptor (PPAR)-modulating therapy for TGCT is being investigated with initial positive outcomes [15], suggesting that PPARγ suppression plays a vital role in the pathogenesis of the tumor. This evidence concerns the gene PPARG and neoplasm.